Boston Scientific Corp
NYSE:BSX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (29.4), the stock would be worth $96.35 (62% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 18.2 | $59.52 |
0%
|
| 3-Year Average | 29.4 | $96.35 |
+62%
|
| 5-Year Average | 28.3 | $92.51 |
+55%
|
| Industry Average | 12.9 | $42.17 |
-29%
|
| Country Average | 14.4 | $46.98 |
-21%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$122.1B
|
/ |
Jan 2026
$5.4B
|
= |
|
|
$122.1B
|
/ |
Dec 2026
$7B
|
= |
|
|
$122.1B
|
/ |
Dec 2027
$7.8B
|
= |
|
|
$122.1B
|
/ |
Dec 2028
$8.8B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
90.4B USD | 18.2 | 30.5 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
166.7B USD | 14 | 25.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.3B USD | 42.5 | 56.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
129.4B USD | 19.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.1B USD | 12.8 | 22.9 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
42.9B EUR | 11.3 | 20.3 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 23.4 | 43.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.5B USD | 30.3 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.2B USD | 10 | 25.4 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
33.8B USD | 11.4 | 15.8 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32.9B USD | 15.2 | 21.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Boston Scientific Corp
Glance View
In the world of medical devices, Boston Scientific Corp. has carved out a significant niche, navigating the intersection of innovation and healthcare with precision. Founded in 1979, the company has built a robust reputation for developing a diverse range of products that address complex medical conditions. Boston Scientific operates through various segments, primarily focusing on interventional medical specialties that target areas such as cardiology, endoscopy, and neuromodulation. Through its relentless pursuit of innovation, the company continues to push boundaries, enhancing the diagnostic and therapeutic capabilities of physicians worldwide. The heartbeat of its operations lies in its extensive research and development endeavors, where cutting-edge technology meets advanced medical knowledge to produce life-enhancing solutions. At its core, Boston Scientific makes money by designing, manufacturing, and selling medical devices used in minimally invasive procedures. Its product portfolio includes solutions for coronary artery disease, heart rhythm disorders, peripheral artery disease, and many other critical ailments. By partnering with healthcare providers, Boston Scientific enables hospitals and clinics to offer high-quality, efficient care that caters to patient needs in a cost-effective manner. Revenue streams flow through direct sales channels and strategic partnerships across global markets, reflecting a combination of organic growth and strategic acquisitions. Moreover, the company actively reinvests in future technologies, ensuring its position as a pioneer in medical advancements while meeting the ever-evolving demands of the industry.
